By measuring the level of a specific protein in the blood, a team of researchers succeeded in detecting the presence of this neurodegenerative disease before the first symptoms appear.
France, environ 900 000 personnes sont atteintes par cette maladie qui entraîne une destruction progressive et irréversible des cellules du cerveau. Un diagnostic précoce permet de mettre rapidement en place une prise en charge adaptée à chaque patient. Aujourd’hui, le traitement et le dépistage des patients atteints par cette maladie sont au cœur des missions des chercheurs du monde entier." data-reactid="24">A discovery that brings hope for many families. Today, Alzheimer’s disease is the most common neurodegenerative disease. In France, approximately 900,000 people are affected by this disease which causes a progressive and irreversible destruction of brain cells. An early diagnosis makes it possible to quickly set up a treatment adapted to each patient. Today, the treatment and screening of patients with this disease are at the heart of the missions of researchers around the world.
International Conference. “data-reactid =” 25 “> A new international study could make a difference. Indeed, a new blood test would be able to detect the presence of Alzheimer’s disease until twenty years before it declares itself. The findings of this study were published in the Journal of the American Medical Association (JAMA) and presented at the Alzheimer’s Association International Conference.
A test to be perfected
international collaborative effort. . And to add: “Although more work is needed to optimize the test and test it in other people before it becomes available in the clinic, the blood test could become particularly useful in improving recognition, diagnosis and care of people in primary care”.” data-reactid=”28″>“The p-tau217 blood test shows great promise in the diagnosis, early detection and study of Alzheimer’s disease”Said Oskar Hansson, MD, PhD, clinical memory research professor at Lund University, Sweden, who leads the Swedish study BioFINDER and senior study author who led the international collaborative effort. . And to add: “Although more work is needed to optimize the test and test it in other people before it becomes available in the clinic, the blood test could become particularly useful in improving recognition, diagnosis and care of people in primary care”.
